Year: 2023

NEWTOWN, PA, Oct. 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Forian Inc. (Nasdaq:FORA) announces that Max Wygod, Chief Executive Officer and Executive Chairman, and Mike Vesey, Chief Financial Officer, will attend ROTH MKM’s 12th annual Technology Event, which will be held on November 15, 2023, at the Yale Club in New York City. This event will provide investors the opportunity to meet with executive management from approximately 60 public companies. The 40-minute management-investor meetings and networking cocktail reception will provide institutional investors with meaningful interaction with executive management to gain in-depth insights. To learn more and submit a registration request, visit www.roth.com/newyork2023. About ROTH MKM: ROTH MKM is a relationship-driven investment bank focused on serving growth companies and...

In collaboration with Nuverse, the two companies continue to enrich the MARVEL SNAP experience with creative seasonal assets and engaging monthly developer diariesMARVEL SNAPMARVEL SNAPSANTA MONICA, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a global leader in delivering immersive experiences across the world’s largest metaverse platforms, is thrilled to celebrate one year of a fruitful partnership with Nuverse, the video game development and publishing subsidiary of Bytedance. Together, they have been creating monthly in-game and social media content for the hit mobile title MARVEL SNAP. Since its launch in November 2022, MARVEL SNAP has garnered both critical acclaim and a dedicated fan following. The game reached a remarkable milestone of over 12 million downloads within its first month alone....

COLUMBIA, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) — BigBear.ai (NYSE: BBAI), a leading provider of AI-powered business intelligence solutions, today announced that Thomas Jefferson University Hospital is expanding its use of BigBear.ai’s AI platform to make day-to-day operations improvements to centralized resource and bed management, nurse staffing, and its transfer center. BigBear.ai’s FutureFlow RX Predictive AI platform allows hospitals to create ‘digital twins.’ Hospitals can then apply likely future operational scenarios to their digital twins, seeing how the digital twin hospital responds to myriad stresses. This predictive knowledge empowers hospitals to plan and execute more efficiently and effectively. “BigBear.ai is thrilled to expand its work with Thomas Jefferson University Hospital,” said Greg Goldwater, Chief Growth...

Chao HuangAssistant General Counsel, Investor Relations Specialist at Provident BankISELIN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) — Provident Bank, a leading New Jersey-based financial institution, is pleased to welcome Chao Huang as Assistant General Counsel, Investor Relations Specialist. Mr. Huang is responsible for reviewing and preparing all quarterly earnings documents, analyst presentations, news releases, CEO and CFO scripts, as well as briefing senior management for discussions with investors at conferences, roadshows, and other meetings. In addition, he will support senior management in creating materials related to financial results and strategic objectives including those related to quarterly earnings, conferences, and Investor Day presentations. “I am thrilled to welcome Chao to this important role on our legal...

HOUSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE: SYY) (“Sysco” or the “company”) today announced financial results for its 13-week first fiscal quarter ended September 30, 2023. Key financial results for the first quarter of fiscal year 2024 include the following (comparisons are to the same period in fiscal year 2023):Sales increased 2.6%; U.S. Foodservice volume increased 1.6%; Gross profit increased 4.6% to $3.6 billion; Operating income increased 9.1% to $803.6 million, and adjusted1 operating income increased 10.6% to $854.3 million; EBITDA increased 10.5% to $1.0 billion, and adjusted EBITDA increased 11.7% to $1.0 billion2; EPS3 increased 8.8% to $0.99 and adjusted1 EPS increased 10.3% to $1.07; and Sysco returned approximately $352.9 million of capital to shareholders via $100.0 million of share repurchases...

Ringbrothers to unveil “UNCAGED,” an all-new custom vehicle build, at the Gentex boothGentex Custom Silverado and Vorsheer XOC TrailerGentex’s heavily modified 2021 Chevrolet Silverado Trail Boss (2LT) has been transformed into the ultimate overland vehicle. A companion 2021 Vorsheer XOC (Extreme Overland Camper) featuring the same overland theme completes the rig.Ringbrothers UNCAGEDGentex’s SEMA booth will also debut UNCAGED, an all-new custom 1965 Ford Mustang Convertible created by Ringbrothers, one of the nation’s leading custom car builders.Gentex Type-R MirrorThe Gentex Type-R Series mirror is a limited edition, lightweight, minimalist automatic-dimming rearview mirror designed for custom car builds, which debuted on a Ringbrothers vehicle in 2015.LAS VEGAS, Oct. 31, 2023 (GLOBE NEWSWIRE) —...

BOTHELL, Wash., Oct. 31, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge trial with its broad-spectrum, oral PB2 inhibitor CC-42344 as a potential treatment for pandemic and seasonal influenza A. Cocrystal expects to begin treating influenza-infected subjects in this trial during the fourth quarter of 2023. In late 2022 Cocrystal reported highly favorable safety and tolerability results in the single-ascending and multiple-ascending dose portions of the healthy volunteer Phase 1 trial conducted in Australia. The Phase 2a single-site, double-blind, placebo-controlled human challenge trial will evaluate the safety, viral and clinical measurements...

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Phase 1 clinical trial of XMT-2056. XMT-2056 is a systemically administered Immunosynthen STING-agonist ADC that is designed to target a novel human epidermal growth factor receptor 2 (HER2) epitope and locally activate STING signaling in both tumor-resident immune cells and in tumor cells, providing the potential to treat patients with HER2-high or -low tumors as monotherapy and in combination with standard-of-care agents. “An in-depth analysis of...

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, taking place from November 6-7, 2023 in New York City. Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceAdam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in New York on Tuesday, November 7 at 10:30 am ET.Interested parties can...

INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition. Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with...